SCHEMBL22166113

SCHEMBL22166113

CCCCCCc1ncc(F)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGBL2 Q5U5Z8 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PTGS2 P35354 2/20 0.35
HTR2A P28223 1/20 0.35
KCNH2 Q12809 1/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
ALOX5 P09917 1/20 0.35
TYR P14679 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19304135 0.93 AGBL2 (0.39) AGBL2TDP1L3MBTL1MEN1MAPT
SCHEMBL10115987 0.85 AGBL2 (0.41) AGBL2TP53CYP3A4HTTKDM4E
SCHEMBL13952474 0.83 TDP1 (0.38) TDP1L3MBTL1PTGS2HTR2AMEN1
SCHEMBL21503703 0.79 TSHR (0.42) TDP1L3MBTL1MEN1KMT2ATSHR
SCHEMBL21859472 0.78 AR (0.35) AGBL2TDP1L3MBTL1PTGS2CYP3A4
SCHEMBL10264384 0.77 AGBL2 (0.43) AGBL2CYP3A4
SCHEMBL21988047 0.75 RAB9A (0.37) MEN1MAPTKMT2ATP53TYR
SCHEMBL30279707 0.75 RAB9A (0.37) MEN1MAPTKMT2ATP53TYR
SCHEMBL1396051 0.75 AGBL2 (0.38) AGBL2TDP1MEN1KMT2A
SCHEMBL29877399 0.75 AGBL2 (0.38) AGBL2TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10695337-B2 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors INCYTE HOLDINGS CORPORATION (US) 2020-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10695337-B2 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors JAK1, JAK2, JAK3 AGBL2 3307/4885TDP1 2098/4885L3MBTL1 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.